Join
Live feed
·
PRReleasevia Quantisnow
Aurinia Pharmaceuticals Inc logo

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

ByQuantisnow·Wall Street's wire, on your screen.
AUPH· Aurinia Pharmaceuticals Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AUPH (Aurinia Pharmaceuticals Inc) and more on Quantisnow.

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development | Quantisnow